Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have received an average recommendation of “Moderate Buy” from the fourteen brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $12.9091.

Several research analysts recently commented on CMPX shares. Canaccord Genuity Group decreased their target price on shares of Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, April 28th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research note on Tuesday, April 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Monday, April 20th. D. Boral Capital reaffirmed a “buy” rating and issued a $30.00 target price on shares of Compass Therapeutics in a research note on Monday, April 27th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $24.00 target price on shares of Compass Therapeutics in a research note on Monday, April 27th.

Compass Therapeutics Stock Performance

Shares of CMPX opened at $2.19 on Friday. The firm has a market cap of $394.40 million, a price-to-earnings ratio of -5.34 and a beta of 0.89. Compass Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $6.88. The firm has a 50 day moving average price of $2.33 and a 200-day moving average price of $4.48.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Tuesday, May 5th. The company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). As a group, equities research analysts predict that Compass Therapeutics will post -0.42 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Suvretta Capital Management LLC increased its position in Compass Therapeutics by 0.6% during the 4th quarter. Suvretta Capital Management LLC now owns 14,182,379 shares of the company’s stock valued at $76,159,000 after purchasing an additional 81,220 shares during the period. Vivo Capital LLC increased its position in Compass Therapeutics by 57.9% during the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock valued at $33,409,000 after purchasing an additional 3,502,000 shares during the period. BVF Inc. IL increased its position in Compass Therapeutics by 63.5% during the 4th quarter. BVF Inc. IL now owns 7,764,842 shares of the company’s stock valued at $41,697,000 after purchasing an additional 3,014,842 shares during the period. Vanguard Group Inc. increased its position in Compass Therapeutics by 45.6% during the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock valued at $24,720,000 after purchasing an additional 2,212,794 shares during the period. Finally, State Street Corp increased its position in Compass Therapeutics by 57.4% during the 4th quarter. State Street Corp now owns 4,890,525 shares of the company’s stock valued at $26,262,000 after purchasing an additional 1,784,012 shares during the period. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.